

13 July 2021

COLLABORATION TARGETS GLOBAL MYCOTOXIN ANIMAL FEED ADDITIVES INDUSTRY

Emerging mineral processing technology company, Zeotech Limited (ASX:ZEO, "Zeotech" or "the Company") is pleased to announce that it has provided a range of Type A molecular sieve zeolites to a leading Australian manufacturer of advanced animal feed additives 'Bioproton', for in-vitro screening of mycotoxin binding, across seven toxins.

Zeotech and Bioproton will assess the initial test results to evaluate the potential of utilising synthetic zeolites to develop targeted mycotoxin binder product(s).

The global mycotoxin detoxifier additives market (binder/adsorbents) is valued at over AUD \$1.1 billion and growing at 5% per annum¹.

Mycotoxins are naturally occurring toxins produced by certain moulds (filamentous fungi), many of which have been implicated as chemical progenitors of toxicity in humans and animals and can be the source of various negative health effects. They can cause a toxic response (mycotoxicosis) when ingested posing a significant health danger to livestock, horses, companion animals, and humans.

Mycotoxins reduce weight gain and growth rate and increase mortality. Some of the effects include tumour growth, anaemia, kidney and liver damage, reproductive disorders, and immunosuppression.

The moulds that create mycotoxin (in animal feeds) develop on various foodstuffs, corn, grains, and various other crops. They can occur in the field (depending on weather conditions), after harvest (depending on conditions), during storage (improper storage), or on the food under warm and humid conditions - as a consequence of climate change, mycotoxins are increasing occurring.

The objective of the program is to progress to a comprehensive commercial collaboration with Bioproton.

Zeotech has provided 3A, 4A and 5A molecular sieve zeolites for the program, which will incorporate the following 7 mycotoxin tests across under 2 pH conditions (acid and neutral). The toxins to be tested are:

- Aflatoxin B1;
- Fumonisin B1;
- Deoxynivalenol;
- Ochratoxin A;
- Zearalenone;

¹ DSM Presentation 'DSM to add world leading animal nutrition and health business with acquisition of Eber Group' June 2020

- T-2 Toxin; and
- Ergotamine.

The testing fees for mycotoxin in-vitro screening program are not material to the Company.

Bioproton, General Manager Juhani von Hellens commented:

“Bioproton remains focused on developing high-quality additives, which are unique and relevant to the global feed industry.

Zeolites are unique adsorbents, and our aim is to leverage outcomes of this preliminary mycotoxin testing program, to support further commercial collaboration, with Zeotech.”

Zeotech, Managing Director Peter Zardo added :

“Climate change is increasing the proliferation of mycotoxins, which will have a detrimental impact on global protein production.

Zeotech is committed to new product development and values the opportunity to work with Bioproton, a leading and innovative manufacturer of high-quality animal feed additives.

This is another example of where Zeotech’s patent-pending technology is applicable to a high-value industry. Mycotoxin feed additives is a billion-dollar industry and is playing an increasingly critical role in sustainable food production.”

This Announcement has been approved by the Board.

- End -

For further information please contact:

Peter Zardo – Managing Director
peter@zeotech.com.au
Tel: (+61) 7 3181 5523

Neville Bassett - Company Secretary
info@zeotech.com.au
Tel: (+61) 7 3181 5523

About Bioproton

Bioproton is a developer and manufacturer of enzyme, probiotic, surfactant, and other high-quality feed additives – with sales in over 45 countries and are committed to evolving via innovative research and development that delivers novel products for the growing global feed market.

Bioproton has been a recipient of Australian Government awards and grants, such as Premier’s Export Awards (finalist in Agricultural Category 2012), Australian Research Council (ARC) Grants and Commercialisation Australia (CA) Grants. In 2017, Westpac nominated Bioproton as one of the top 20 ‘Businesses of Tomorrow’ companies in Australia.

About Zeotech

Zeotech Limited (ASX: ZEO) holds proprietary mineral processing technology developed by The University of Queensland, for the low-cost production of advanced materials ‘synthetic zeolites’ and aims to utilise their unique properties for a sustainable future.

www.zeotech.com.au

Zeotech Limited | ASX: ZEO

ACN 137 984 297

Level 27, Santos Place, 32 Turbot Street, Brisbane QLD 4000

P: +61 7 3181 5523 | E: info@zeotech.com.au

The strategy focuses on the manufacture of low-cost molecular sieve synthetic zeolites for global markets. The Company is developing innovative environmental management solutions, which include cleantech for lithium refineries to commercially manage by-product residue and developing economically viable carbon capture and conversion solutions, underpinned by low-cost 'adsorbents and catalysts' manufactured using Zeotech's patent-pending technology.

About Zeolites

Synthetic zeolites are manufactured aluminosilicate minerals with a sponge-like structure, made up of tiny pores (frameworks) that make them useful as catalysts or ultrafine filters. They are commonly known as molecular sieves and can be designed to selectively adsorb molecules or ions dependant on their unique construction.

Zeolites play an important role in a cleaner and safer environment.

- zeolites are an effective substitute for harmful phosphates in powder detergent, now banned in many parts of the world because of blue green algae toxicity in waterways;
- as catalysts, zeolites increase process efficiencies, decrease in energy consumption;
- zeolites can act as solid acids and reduce the need for more corrosive liquid acids;
- zeolites adsorbent capabilities see them widely used in water treatment i.e., heavy metal removal including those produced by nuclear fission; and
- as redox catalyst sorbents, zeolites can help remove exhaust gases and CFC's.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Zeotech and certain of the plans and objectives of Zeotech with respect to these items.

These forward-looking statements are not historical facts but rather are based on Zeotech current expectations, estimates and projections about the industry in which Zeotech operates, and its beliefs and assumptions.

Words such as "anticipates," "considers," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Zeotech, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Zeotech cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Zeotech only as of the date of this release.

www.zeotech.com.au

Zeotech Limited | ASX: ZEO

ACN 137 984 297

Level 27, Santos Place, 32 Turbot Street, Brisbane QLD 4000
P: +61 7 3181 5523 | E: info@zeotech.com.au



The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Zeotech will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

www.zeotech.com.au

Zeotech Limited | ASX: ZEO

ACN 137 984 297

Level 27, Santos Place, 32 Turbot Street, Brisbane QLD 4000

P: +61 7 3181 5523 | E: info@zeotech.com.au